Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.32
Peer-review started: August 21, 2023
First decision: November 28, 2023
Revised: November 30, 2023
Accepted: December 15, 2023
Article in press: December 15, 2023
Published online: January 6, 2024
Prostate cancer (PCa) is a widespread malignancy, predominantly affecting elderly males, and current methods for diagnosis and treatment of this disease continue to fall short. The marker Ki-67 (MKI67) has been previously demon
To explore the diagnostic and prognostic efficacy of antigens identified by MKI67 expression in PCa.
For cohort 1, the efficacy of MKI67 diagnosis was evaluated using data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) data
In cohort 1, MKI67 expression was correlated with prostate-specific antigen (PSA), Gleason Score, T stage, and N stage. The receiver operating characteristic (ROC) curve showed a strong diagnostic ability, and the Kaplan-Meier method demon
MKI67 expression was positively associated with the Gleason Score, T stage, and N stage and showed a strong diagnostic and prognostic ability in PCa.
Core Tip: Marker Ki-67 (MKI67) has been established to correlate with the proliferation and metastasis of various malignant tumor cells, including those implicated in prostate cancer (PCa). Our objective is to validate the connection between MKI67 and the diagnosis as well as prognosis of PCa, by deploying two distinct patient cohorts from bioinformatics and clinical data. Within the bioinformatics data cohort, comprising 496 PCa tissue samples juxtaposed with 152 normal controls, we ascertained that MKI67 possesses a strong diagnostic ability for PCa along with a moderate prognostic prediction potential. Similarly, through our retrospective analysis of clinical data from 271 PCa patients, we confirmed the potent diagnostic capacity of MKI67 for PCa and its capability to predict prognosis to a certain extent.